Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism

Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of trelagliptin, which exhibited approximately 4- and 12-fold more potent inhibition against human dipepti...

Descripción completa

Detalles Bibliográficos
Autores principales: Grimshaw, Charles E., Jennings, Andy, Kamran, Ruhi, Ueno, Hikaru, Nishigaki, Nobuhiro, Kosaka, Takuo, Tani, Akiyoshi, Sano, Hiroki, Kinugawa, Yoshinobu, Koumura, Emiko, Shi, Lihong, Takeuchi, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915685/
https://www.ncbi.nlm.nih.gov/pubmed/27328054
http://dx.doi.org/10.1371/journal.pone.0157509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915685/
https://www.ncbi.nlm.nih.gov/pubmed/27328054
http://dx.doi.org/10.1371/journal.pone.0157509

Ejemplares similares